Platinum-Resistant Ovarian Carcinoma — Trials

Platinum-Resistant Ovarian Carcinoma — Trials · CancerIndex

Clinical trials

Registered studies

109 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.

Active: 56
Recruiting: 29
Ph III recruiting: 3
Growth YoY: —
Industry share: 48%
Top sponsor: National Cancer Institute (NCI)
Termination share: 52.3%

Computedformula ci-trial-intel-v1 · interventional studies · entity + NCIt descendants · hover a figure for its formulaCompare cancers Terminated studies (24)

clinicaltrialsPublishedShowing 1–4 of 4 studies matching the filters · status and phase as posted by the registrant; each row links to the study record.

NCT	Title	Status	Phase	Enrollment (n)	Sponsor	Countries	Last update	Source
NCT04787289	A Comparison of 2 Standard Doses of Bevacizumab in Combination With Chemotherapy in Epithelial Ovarian Cancer	unknown	Phase 2	244	British Columbia Cancer AgencyOTHER	1	Aug 7, 2024	clinicaltrials
NCT05310344	Albumin-bound Paclitaxel and Bevacizumab for Platinum-resistant Recurrent Ovarian Cancer	unknown	Phase 2	50	Lei LiOTHER	1	Apr 4, 2022	clinicaltrials